Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Combined With Retlirafusp Alfa in HER2 2+/3+ Gastric/GEJ Adenocarcinoma
NCT07817654Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Sep 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab rezetecan and retlirafusp alfa in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Henan Cancer Hospital. Primary endpoint: Objective Response Rate. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecanretlirafusp alfa
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07817654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07817654.